Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.
Mereo Biopharma Group plc (MREO) is a clinical-stage biopharmaceutical leader developing innovative treatments for rare diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical progress, strategic partnerships, and regulatory developments.
Our curated collection features official press releases and verified news covering critical milestones including clinical trial results, regulatory submissions, and strategic collaborations. Track updates across Mereo's pipeline targeting conditions like osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.
All content undergoes rigorous verification to ensure accuracy and relevance. For comprehensive tracking of Mereo's progress in rare disease therapeutics, bookmark this page for direct access to primary source materials and expert analysis of corporate developments.
Mereo BioPharma (NASDAQ: MREO) reported its full year 2024 financial results and corporate updates. The company's Phase 3 Orbit study of setrusumab in osteogenesis imperfecta is advancing toward a second interim analysis expected mid-2025. Alvelestat received European Commission Orphan Designation for Alpha-1 Antitrypsin Deficiency-associated Lung Disease treatment.
Financial highlights include cash position of $69.8 million as of December 31, 2024, expected to fund operations into 2027. R&D expenses increased to $20.9 million from $17.4 million in 2023, while general and administrative expenses rose to $26.4 million from $18.4 million. The company reported a net loss of $43.3 million for 2024, compared to $29.5 million in 2023.
Two global studies are progressing: the Phase 3 Orbit study and Cosmic study, evaluating setrusumab in OI patients. Pre-commercial activities are ongoing in Europe, with scientific advice obtained from GBA in Germany and NICE in the U.K.
Mereo BioPharma Group (NASDAQ: MREO), a clinical-stage biopharmaceutical company specializing in rare diseases, has announced its participation in the Leerink Partners Global Healthcare Conference.
The company's CEO, Dr. Denise Scots-Knight, will engage in a fireside chat scheduled for March 12, 2025, at 8:40 am ET / 1:40 pm GMT.
Investors and interested parties can access the live audio webcast through the Investors section at www.mereobiopharma.com/investors. A replay of the presentation will remain available on the company's website for two weeks after the event.
Mereo BioPharma (NASDAQ: MREO) provided updates on its lead clinical programs. The Phase 3 Orbit Study of setrusumab for Osteogenesis Imperfecta (OI) is progressing toward a second interim analysis expected in mid-2025, with potential final analysis in Q4 2025. The Cosmic study, evaluating setrusumab against bisphosphonate therapy in younger patients, continues in parallel.
Alvelestat, their treatment for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), received a positive opinion from EMA's Committee for Orphan Medicinal Products, with final European Commission decision expected in Q1 2025. The drug previously received FDA Orphan Drug and Fast Track Designations.
The company confirmed its current cash position will fund operations into 2027, supporting key development milestones through 2025.
Mereo BioPharma Group (NASDAQ: MREO) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Dr. Denise Scots-Knight, is scheduled to present on Thursday, January 16, 2025, at 8:15am PT / 04:15pm GMT.
The presentation will be accessible through a live audio webcast via the Investors section of Mereo's website at www.mereobiopharma.com/investors. For those unable to attend live, an archived version of the webcast will remain available on the company's website for a two-week period following the event.
Mereo BioPharma Group (NASDAQ: MREO) has announced its participation in the Jefferies London Healthcare Conference. Dr. Denise Scots-Knight, CEO, will engage in a Fireside Chat on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT. The presentation will be accessible via live audio webcast through the Investors section of Mereo's website, with a replay available for two weeks after the event.
Mereo BioPharma reported Q3 2024 financial results with cash position of $80.5 million, expected to fund operations into 2027. The company's setrusumab received Breakthrough Therapy designation from FDA for osteogenesis imperfecta treatment. Q3 net loss increased to $15.0 million from $6.5 million in Q3 2023, primarily due to foreign exchange losses. R&D expenses decreased 12% to $3.2 million, while G&A expenses increased 9% to $6.2 million. The company continues to advance setrusumab's Phase 3 program with partner Ultragenyx and expects alvelestat to be Phase 3-ready by end of 2024.
Mereo BioPharma Group (NASDAQ: MREO), a clinical-stage biopharmaceutical company specializing in rare diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. Dr. Denise Scots-Knight, CEO of Mereo, will engage in a Fireside Chat on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST.
Interested parties can access a live audio webcast of the event through the Investors section of Mereo's website at www.mereobiopharma.com/investors. For those unable to attend live, an archived replay of the webcast will be available on the company's website for two weeks following the event, providing an opportunity for stakeholders to stay informed about Mereo's latest developments and insights in the rare disease sector.
Mereo BioPharma (NASDAQ: MREO) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Cash position of $87.4 million as of June 30, 2024, expected to fund operations into 2027
- Phase 3 Orbit and Cosmic studies of setrusumab in OI fully enrolled
- New long-term Phase 2 data showed continued 67% reduction in fracture rates after 14 months of setrusumab treatment
- R&D expenses increased to $4.9 million, up 33% year-over-year
- Net loss of $12.3 million for Q2 2024, compared to $1.8 million in Q2 2023
The company continues to make progress on setrusumab for OI and alvelestat for AATD, with multiple potential value inflection points ahead.
Mereo BioPharma Group plc (NASDAQ: MREO), a clinical-stage biopharma firm focused on rare diseases, has announced a $50 million underwritten offering of 12,531,300 American Depositary Shares (ADS). Each ADS is priced at $3.99, representing five ordinary shares. The offering is set to close on June 17, 2024. Net proceeds will fund the setrusumab program and other corporate purposes. Investors include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors, alongside existing shareholders like Rubric Capital Management and Janus Henderson Investors. Jefferies, Leerink Partners, and Cantor are managing the offering.
Mereo BioPharma (NASDAQ: MREO), a clinical-stage biopharmaceutical company specializing in rare diseases, announced that CEO Dr. Denise Scots-Knight will participate in a Fireside Chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 11:00am ET / 04:00pm BST. A live webcast will be available on Mereo's investor website, with a replay accessible for two weeks post-event.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
